Back
Summit Therapeutics Stock Predictions
Spencer Rascoff co-founded Zillow, scaling it to a $16B valuation. But everyday investors couldn't invest until the IPO, missing early gains.
This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.
Buy
54
SMMT
Summit Therapeutics
Last Price:
$23.88
Seasonality Move:
8.71%
7 Day Trial
ALL ACCESS PASS
$
7
Top investors are buying this "unlisted" stock
This is a paid advertisement for Pacaso's Regulation A offering. Please read the offering circular and related risks at invest.pacaso.com.Summit Therapeutics Stock Forecast
-
Over the next 52 weeks, Summit Therapeutics has on average historically risen by 63.8% based on the past 10 years of stock performance.
-
Summit Therapeutics has risen higher in 7 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 70%
-
Is Summit Therapeutics Stock Undervalued?The current Summit Therapeutics [SMMT] share price is $23.87. The Score for SMMT is 54, which is 8% above its historic median score of 50, and infers lower risk than normal.
-
SMMT is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
Will Summit Therapeutics Stock Go Up Next Year?
-
Over the next 52 weeks, Summit Therapeutics has on average historically risen by 63.8% based on the past 10 years of stock performance.
Summit Therapeutics Stock Rating
Buy
54
Summit Therapeutics (SMMT)
is a Buy
Is Summit Therapeutics overpriced?
-
Summit Therapeutics has risen higher in 7 of those 10 years over the subsequent 52-week period, corresponding to a historical accuracy of 70%
Summit Therapeutics Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
smmttx.com
52-Week Data
52-Week High:
36.91
52-Week Low:
2.10
Prediction Charts
Market Cap:
17.7B
Price in USD:
23.87
Volume:
1.7M
Beta:
-0.18
Technical Analysis
SMA50:
22.40
SMA100:
21.16
SMA200:
19.54
52-Wk Change:
429.27%
Stock Predictions
-
Is Summit Therapeutics stock public?Yes, Summit Therapeutics is a publicly traded company.
-
What is the Summit Therapeutics stock quote today?The Summit Therapeutics stock price is 23.87 USD today.
-
How to buy Summit Therapeutics stock online?You can buy Summit Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Apr-29 | 23.70 | 23.62 | 24.54 | 23.20 |
| Apr-30 | 22.98 | 24.12 | 24.35 | 22.84 |
| May-1 | 24.38 | 24.67 | 25.21 | 23.42 |
| May-2 | 25.93 | 27.90 | 29.99 | 25.81 |
| May-5 | 27.90 | 28.02 | 28.28 | 26.71 |
| May-6 | 26.95 | 24.20 | 27.09 | 23.81 |
| May-7 | 24.54 | 24.29 | 24.73 | 23.80 |
| May-8 | 24.48 | 24.65 | 25.79 | 23.96 |
| May-9 | 24.65 | 23.96 | 25.34 | 23.45 |
| May-12 | 23.26 | 25.26 | 25.30 | 23.26 |
| May-13 | 25.39 | 24.61 | 25.50 | 24.21 |
| May-14 | 24.50 | 22.75 | 25.07 | 22.51 |
| May-15 | 22.50 | 23.09 | 23.34 | 21.75 |
| May-16 | 23.14 | 23.87 | 23.94 | 23.04 |
Summit Therapeutics Earnings
Summit Therapeutics Earnings Report: Per Share Summit Therapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.
Summit Therapeutics Forecast Revenue Growth
Summit Therapeutics Stock Analysis: Historical quarterly revenues per share for Summit Therapeutics and historical quarterly revenue growth:
-
Analysts estimate an earnings decrease this quarter of $0.03 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.10 per share, and a decrease next year of $0.11 per share.
* Summit Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.